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Abstract
Many immunotherapies rely on the presence of
neoepitopes derived from somatic mutations that lead
to altered peptide sequences. Several studies have
now analyzed the neoepitope landscape of different
cancer subtypes, predominantly for adult samples,
which tend to feature significantly higher mutational
burden. However, a new report publishing the first
comprehensive analysis of the pediatric neoepitope
landscape suggests that immunotherapies could also
hold promise for pediatric cancers.
Keywords: Exome sequencing, Immunotherapy,
Neoepitope, Personalized cancer vaccine, RNA
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Leveraging the adaptive immune system in
cancer treatment
There is now an impressive array of diverse strategies for
leveraging the immune system as a promising treatment
avenue in several cancer types [1]. A subset of these
involve the adaptive immune system, whereby T cells are
directed to tumor cells presenting a tumor-specific mutant
antigen that is recognized by a receptor on the T cell [2].
The tumor-specific antigen corresponds to any somatic
mutation that results in a protein coding difference compared with the wild-type protein sequence. After intracellular processing and cleavage within the tumor cell, each
mutant protein sequence can result in one or more
distinct peptides of 8–15 amino acids [3]. A subset of
these peptides, referred to as neoepitopes, are bound by
major histocompatibility complex (MHC) class I or II
molecules (encoded by HLA genes) and presented on the
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surface of the tumor cell, where they can be recognized by
CD8+ or CD4+ T cells, respectively. T-cell receptor (TCR)
sequence diversity resulting from recombination at
TCR loci allows for the potential recognition of almost
any peptide sequence and, by extension, almost any
tumor-specific neoepitope. Upon successful formation
of a TCR–MHC–peptide complex, a signal cascade
triggers apoptosis and death of the recognized tumor
cell. Elucidating each of the major components of this
process has been enabled by recent developments in
next-generation sequencing. An emerging discipline of
‘immunogenomics’ seeks to systematically characterize
the diversity of HLA alleles, identify patient-specific
HLA haplotypes, identify tumor-specific neoepitopes,
predict peptide–MHC binding affinities, match these to
specific TCR sequences, and track overall changes in the
TCR repertoire [1]. Several relatively recent cancertreatment modalities have particularly benefited from these
advances in immunogenomic profiling and analysis. For
example, several studies have used the neoepitope burden
to predict which patients might respond to checkpointblockade inhibition therapies [4, 5]. In addition, personalized cancer vaccines rely entirely upon identifying a set of
promising neoepitopes for each patient [6].

Neoepitope landscapes as an indicator of
immunotherapy potential
In this issue of Genome Medicine, Chang and colleagues [7] report the first comprehensive analysis of
the neoepitope landscape specifically for pediatric
cancers. This landscape joins several others that have
focused on pan-cancer analysis of the (mostly) adult
tumors represented in The Cancer Genome Atlas
(TCGA) project [8] or specific cancer types [9]. From
540 primary tumors, Chang and colleagues identified at
least one predicted neoepitope in 78.1, 88.4, and 89.8%
of pediatric central nervous system, leukemia, and solid
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malignancies, respectively. This finding is remarkable
and of potential clinical significance owing to the relatively low mutation burden of most pediatric tumors
compared with those observed in adults, particularly
those associated with prolonged environmental exposures (e.g., smoking for lung cancer and UV for melanoma). Childhood tumors are also often characterized
by structural variation; thus, the authors wisely considered RNA expression data, where available, to predict neoepitopes arising from gene fusions in addition
to single-nucleotide variants (SNVs). After requiring
evidence for RNA expression of each candidate, an estimated 60% of tumors had at least one predicted
neoepitope. While many additional factors (several of
which are discussed below) remain to be incorporated
into neoepitope landscapes for patient cohorts and
individual patients, the study provides a promising
overview of the potential efficacy of adaptive immunetherapy approaches in pediatric cancer.

Accurate neoepitope identification for
personalized medicine
Chang and colleagues used whole-genome sequencing
(WGS) and RNA-seq data to identify two types of
somatic variants, specifically SNVs and RNA fusions. For
each somatic variant, distinct peptide nonamers were

extracted by tiling across the SNV or fusion junction
position. HLA alleles and nonamers for each patient
were used to predict the peptide–MHC binding affinity
using a single algorithm. There are several ways in which
developing neoepitope-prediction methods could improve such efforts in the future. In addition to the SNVs
considered by most studies, insertions and deletions,
particularly those resulting in frameshifts, might prove a
rich source of neoepitopes [10]. Two of the most comprehensive neoepitope landscape reports to date—Charoentong et al. [8] and Chang et al.—do not appear
to consider insertions or deletions in their neoepitope
identification, likely because most existing software
packages do not yet support neoepitope prediction for
indels. However, unlike most previous studies, Chang
and colleagues did incorporate neoepitope prediction
from gene fusions. A conceptually similar but untapped
source of novel peptide epitopes are those created by
tumor-associated aberrant RNA splicing events. Furthermore, as different transcript isoforms for the same gene
can feature varying reading frames, a single variant
might produce multiple unique mutant peptides.
Therefore, understanding the alternative splicing profile of a tumor will be imperative for identifying which
neoepitopes are actually expressed. Many additional
factors remain unexplored that could prove useful in

Low burden (0–10)

High burden (>10)
PRAD
100
MEL
BRCA
THCA

RB
ALL
LGG
EPD/CPC

75
AML

EWS

Five-year relative overall survival (%)**

Five-year relative overall survival (%)**

100

NBL
OS

MB

HGG

RHB
50

25

Drugs**
5
25
50
Age
Adult
Pediatric

SKCM
BLCA

75
CESC

50

CRC

OV

STAD
25

LIHC
KRP
HNSC
GBM

UCEC

LUAD
LUSC
PAAD

0

0
2.5

5.0

7.5

Neoepitope load (peptides/sample)*

10.0

100

200

300

400

500

600

Neoepitope load (peptides/sample)*

Fig. 1 Five-year relative survival versus neoepitope load in pediatric and adult cancers. Five-year relative survival is plotted against average neoepitope
load for 29 cancer subtypes. Dot size represents the number of therapies approved by the US Food and Drug Administration (range 1 to 67) that are
indicated for each specific disease. Survival data were obtained from the SEER Cancer Statistics Database (https://seer.cancer.gov), and drug counts for
each cancer type were obtained from the A to Z List of Cancer Drugs provided by the National Cancer Institute (https://www.cancer.gov). Neoepitope
load numbers are derived from the analyses presented in Chang et al. [7] and Charoentong et al. [8] for children (blue) and adults (red), respectively.
*Neoepitope loads represent peptide–HLA binding predictions for missense single-nucleotide variants (SNVs) only. **Drug counts and survival rates for
certain displayed subtypes are approximations as the NCI and SEER have grouped cancers differently compared with the sources of neoepitope load
data. Abbreviations: ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma,
CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CRC colon-rectum adenocarcinoma, EPD/CPC ependymomas and choroid
plexus tumor, EWS Ewing sarcoma, GBM glioblastoma multiforme, HGG high-grade glioma, HNSC head and neck squamous cell carcinoma, KRP kidney
and renal pelvis tumors, LGG low-grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell
carcinoma, MB medulloblastoma, MEL melanoma, NBL neuroblastoma, OS osteosarcoma, OV ovarian serous cystadenocarcinoma, PAAD
pancreatic adenocarcinoma, PRAD prostate adenocarcinoma, RB retinoblastoma, RHB rhabdomyosarcoma, SKCM skin cutaneous melanoma,
STAD stomach adenocarcinoma, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma
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prioritizing neoepitopes for use in personalized cancer
vaccines or predicting response to immunotherapy.
For example, the importance of varying the peptide
length or the mutation position within the peptide sequence remains unclear. In addition, cross-reactivity
of neoepitopes with wild-type peptides and how this
affects self/non-self determination by the immune
system is poorly understood. The minimum or optimal
number of peptides required for clinical response also
remains unknown.
Each of these example factors presents an opportunity to improve the process of neoepitope landscape
characterization. Over the past few years, we have
moved from simple mutation burden as a predictor of
possible response to immunotherapy, to neoepitope
burden, and now expressed neoepitope burden. It
seems likely that not all neoepitopes with MHC
binding affinity below an arbitrary threshold (e.g.,
IC50 < 500 nm) are created equal. A weighted neoepitope score that incorporates additional predictive features could lead to more clinically relevant neoepitope
landscapes. Crucial to the development of such a score
will be the publication of large datasets of experimentally
and clinically validated neoepitopes.

Potential for clinical impact of neoepitopes in
pediatric and adult cancers
It is notable that such a high proportion of the pediatric
cases in Chang et al.’s study is identified as having at
least one potential neoepitope. When the neoepitope
landscape is considered in the context of 5-year relative
survival and availability of approved drugs, several
pediatric and adult cancer types appear particularly
promising for response to immunotherapy. For example,
pediatric high-grade glioma (HGG), adult uterine corpus
endometrial cancer (UCEC), and several others are
characterized by relatively high neoepitope burden, low
survival rates and relatively few approved therapies
(Fig. 1). Melanoma (MEL) has shown promising clinical
responses in adult immunotherapy and features an exceptionally high neoepitope load, even in pediatric cases.
Given the understandable limitations of the analyses
completed to date, the potential for application of
immunotherapies in pediatric cancer could be even
more promising than it currently seems. Owing to the
complexities discussed above, it is likely that the existing neoepitope landscapes underestimate the number
of potential tumor-specific mutant antigens. However,
there is also reason for tempered optimism. The
undeniably low neoepitope burden in most pediatric
and some adult tumors poses a challenge in leveraging
a specific immune response. Furthermore, reports of
transient treatment response followed by progressive
disease necessitate further investigation into development
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of resistance to these emerging immunotherapies.
Nevertheless, there is reason to hope that certain cancers with high neoepitope burden and upregulated
checkpoint blockade pathways will respond to either
personalized vaccines or checkpoint blockade inhibition. The combination of these two therapies could
be effective in an even larger proportion of the patient
population. Studies like that of Chang and colleagues
suggest that improving our understanding of the
neoepitope landscape of each tumor type will be a key
component of identifying these patients.
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